Search
for
Sort by
Research 30 of 1000+
- The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
- Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- Data from A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor–Positive Metastatic Breast Cancer
- Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer
- Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
- Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer
- 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
- Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
- Ductal breast cancer in a male patient
- Cancer risk in polycystic ovary syndrome patients: Common treatments and future perspectives
- Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
- Drug safety evaluation of exemestane
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- Androgen receptor: A promising therapeutic target in breast cancer
- Aromatase inhibitors induce ‘male pattern hair loss’ in women?
- Estrogens and aging skin
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- The evolution of primary multimodality treatment in resectable breast cancer
- Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- 200 The relationship between the expression of cytokeratin 5/6 and clinicopathologic factors in invasive breast carcinoma
- Nutraceuticals Known To Promote Hair Growth Do Not Interfere With The Inhibitory Action of Tamoxifen In MCF7, T47D And BT483 Breast Cancer Cell Lines
- A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
- Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling